Joseph Witztum

Professor, Division of Endocrinology & Metabolism at University of California San Diego - School of Medicine

Joseph Witztum

Joseph Witztum

Professor, Division of Endocrinology & Metabolism at University of California San Diego - School of Medicine

Biography

Joseph L. Witztum is Professor of Medicine at the University of California San Diego.

Overview
RelSci Relationships

186

Number of Boards

2

Relationships
RelSci Relationships are individuals Joseph Witztum likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief, Division of Gastroenterology at University of California San Diego Health System

Relationship likelihood: Strong

Co-Founder at uniQure NV

Relationship likelihood: Strong

Former President & Chief Executive Officer at Akcea Therapeutics, Inc.

Relationship likelihood: Strong

Director-Vascular Medicine at University of California San Diego - School of Medicine

Relationship likelihood: Strong

Interim Chief Executive Officer at Akcea Therapeutics, Inc.

Relationship likelihood: Strong

Director, Center for Cardiovascular Disease Prevention at The Brigham & Women's Hospital, Inc.

Relationship likelihood: Average

Former Member, Clinical Advisory Board at Vascular Biogenics Ltd.

Relationship likelihood: Average

Former Senior Vice President at Massachusetts General Physician's Organization, Inc.

Relationship likelihood: Average

Scientific Advisor at SetPoint Medical Corp.

Relationship likelihood: Average

Executive Director of Patient Advocacy at Akcea Therapeutics, Inc.

Relationship likelihood: Average

Paths to Joseph Witztum
Potential Connections via
Relationship Science
You
Joseph Witztum
Professor, Division of Endocrinology & Metabolism at University of California San Diego - School of Medicine
Boards & Committees
Member, Scientific Advisory Board
Current

Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.

Member, Scientific Advisory Board
Prior - 2015

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Joseph Witztum. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Joseph Witztum's profile does not indicate a business or promotional relationship of any kind between RelSci and Joseph Witztum.